INGN Stock Analysis: Buy, Sell, or Hold?
INGN - Inogen Inc
$5.50
-0.11 (-1.96%)
▼
5d:
-3.68%
30d:
-10.57%
90d:
-14.06%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When INGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: INGN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: INGN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: INGN is currently trading at $5.50, which is considered oversold relative to its 30-day fair value range of $5.76 to $6.55. From a valuation perspective, the stock is trading at a discount (Forward PE: -34.4) compared to its historical average (120.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, INGN is in a downtrend. The price is currently testing key support at $5.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.67 (+130.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INGN is in a downtrend. The price is currently testing key support at $5.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.67 (+130.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.76 -
$6.55
Company Quality Score
51/100
(HOLD)
Options IV Signal
52th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
81.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 52th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 130.3% below Wall St target ($12.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.76 -
$6.55
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.63
(11.4%)
Support & Resistance Levels
Support Level
$5.50
Resistance Level
$6.28
Current Trend
Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-34.38
Wall Street Target
$12.67
(+130.3%)
Revenue Growth (YoY)
3.0%
Earnings Growth (YoY)
87.3%
Profit Margin
-6.9%
PE vs Historical
-34.4 vs 120.2
CHEAP
Share & Embed Analysis
Last updated: August 25, 2026 4:22 AM ET
Data refreshes hourly during market hours. Next update: 5:22 AM
Data refreshes hourly during market hours. Next update: 5:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 46 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 60 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 33 SELL |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 44 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$108 | 39 SELL |
